Screening Tool Sample Clauses

Screening Tool. As soon as reasonably practicable following the receipt of Required Antitrust Clearances, the Seller shall use commercially reasonable efforts to procure that the Group Companies (i) initiate the implementation of a commercially available reputable screening tool that is reasonably acceptable to the Purchaser with the goal to have such screening tool available and operative for all Group Companies as soon as practicable after the Closing Date to allow the Group Companies to screen on a daily basis automatically all names in the Group Companies' respective enterprise resource planning (ERP) systems, including, without limitation, all customers, distributors, resellers, suppliers, sales agents, known end users, freight forwarders, carriers, and other intermediaries and (ii) have the persons responsible for monitoring such screening tool undergo correlative training as reasonably required. The implementation may be pursued in a sequenced approach with ELITechGroup SpA, ELITechGroup Inc. and ELITechGroup MDx LLC becoming the pilot for such implementation. Such screening tool shall screen against all applicable sanctions lists, including, without limitation, the Specially Designated Nationals and Blocked Persons List, the Entity List, the Denied Persons List, the Unverified List, and the EU Consolidated Sanctions List.
AutoNDA by SimpleDocs
Screening Tool. Asking patients how they rate their sleep quality overall was a useful screening tool for busy primary health care physicians to assess their patients sleeping habit in a very short time. Self-reported bad sleep quality had specificity of 0.99 and its positive predictive value was 0.99 (see table 22). Further studies could provide evidence supporting the use of this tool. The author suggests the following algorithm based on the patients' self-reported sleep quality. Patient's response Physician's action Bad Evaluate the case, encourage patient to follow sleep hygiene measures, and prescribe non-pharmacological or pharmacological measures accordingly. Average Apply PSQI Questionnaire on the patient and follow up based on results Good Repeat the question on upcoming visits and encourage patient to follow sleep hygiene measures. Very Good Do nothing and encourage patient to follow sleep hygiene measures.
Screening Tool. The following parties are participating in the WestCoast Children’s Clinic Commercial Sexual Exploitation Identification Tool (CSF-IT) pilot project. a. Child Welfare Services i. Assessment & Investigations Unit ii. Ongoing Unit iii. Permanency Unit iv. Transitional Services Unit b. Probation Department i. Juvenile Institution Officers ii. Juvenile Probation Supervision iii. Juvenile Court Intake Officers iv. Probation Officer’s assigned to: CSEC Court c. Mental Health Department i. RISE Clinicians x. Xxxx’x Anchorage i. Shelter Staff WestCoast Children’s Clinic will provide training for the departments and community based agencies as noted above, who will be utilizing the Pilot Screening Tool. This screening tool will be used amongst local agencies to identify CSE or at-risk youth, and be utilized to inform and improve service delivery. The agencies that complete the tool will need to determine the level of risk the youth is at based on the number total from the questions that were answered by the screener. The screener at the agency can refer the youth to services in the community that will meet their needs or continue providing services for them. There are certain questions on the Screening Tool that if marked yes, will require an immediate Suspected Child Abuse Report (SCAR) to Child Welfare Services. For Data Collection purposes, local Community Partners completing the Screening Tool will be asked to submit a copy of screenings, not resulting in a SCAR, to the Department of Social Services, who will track the data. DSS will be responsible for tracking all data that is collected by the individual stake holders. The youth’s name must be redacted by the agency submitting the Screening Tool due to confidentiality. The information required for Data Collection will include: the age of the youth, gender, zip code in which they reside, risk level assessed, services provided, name of agencies the youth is referred, if the youth is identified as being a CSEC victim, and whether a SCAR is made to Child Welfare Services. These items will be available to document as an attachment to the Screening Tool. The redacted copy of the Screening Tool for Data Collection will be sent via fax or mail to:

Related to Screening Tool

  • Screening After you sign and date the consent document, you will begin screening. The purpose of the screening is to find out if you meet all of the requirements to take part in the study. Procedures that will be completed during the study (including screening) are described below. If you do not meet the requirements, you will not be able to take part in the study. The study investigator or study staff will explain why. As part of screening, you must complete all of the items listed below: • Give your race, age, gender, and ethnicity • Give your medical history o You must review and confirm the information in your medical history questionnaire • Give your drug, alcohol, and tobacco use history • Give your past and current medication and treatment history. This includes any over-the-counter or prescription drugs, such as vitamins, dietary supplements, or herbal supplements, taken in the past 28 days • Height and weight will be measured • Physical exam will be done • Electrocardiogram (ECG) will be collected. An ECG measures the electrical activity of the heart • You may be tested for COVID-19 o Blood tests for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C o Blood tests to see how your blood clots ▪ Fibrinogen ▪ PT/INR/aPTT o Blood tests for amylase and lipase (enzymes that help with digestion, Part B only) o Blood tests for a lipid (fats) panel (Part B only) ▪ Total cholesterol ▪ Triglycerides ▪ HDL ▪ Direct HDL o Blood tests to check your thyroid function (Part B and Part C only) ▪ TSH ▪ Free T4 o Urine to test for drugs of abuse (illegal and prescription) o Urine tests to check your albumin/ creatinine ratio o Females who have not had a period for at least 12 months in a row will have a blood hormone test to confirm they cannot have children • The study investigator may decide to do an alcohol breath test • The use of proper birth control will be reviewed (males only) • You will be asked “How do you feel?” HIV, hepatitis B, and hepatitis C will be tested at screening. If anyone is exposed to your blood during the study, you will have these tests done again. If you have a positive test, you cannot be in or remain in the study. HIV is the virus that causes acquired immunodeficiency syndrome (AIDS). If your HIV test is positive, you will be told about the results. It may take weeks or months after being infected with HIV for the test to be positive. The HIV test is not always right. Having certain infections or positive test results may have to be reported to the State Department of Health. This includes results for HIV, hepatitis, and other infections. If you have any questions about what information is required to be reported, please ask the study investigator or study staff. Although this testing is meant to be private, complete privacy cannot be guaranteed. For example, it is possible for a court of law to get health or study records without your permission.

  • Compatibility 1. Any unresolved issue arising from a mutual agreement procedure case otherwise within the scope of the arbitration process provided for in this Article and Articles 25A to 25G shall not be submitted to arbitration if the issue falls within the scope of a case with respect to which an arbitration panel or similar body has previously been set up in accordance with a bilateral or multilateral convention that provides for mandatory binding arbitration of unresolved issues arising from a mutual agreement procedure case. 2. Nothing in this Article and Articles 25A to 25G shall affect the fulfilment of wider obligations with respect to the arbitration of unresolved issues arising in the context of a mutual agreement procedure resulting from other conventions to which the Contracting States are or will become parties.”.

  • Evaluation Software If the Software is an evaluation version or is provided to You for evaluation purposes, then, unless otherwise approved in writing by an authorized representative of Licensor, Your license to use the Software is limited solely for internal evaluation purposes in non-production use and in accordance with the terms of the evaluation offering under which You received the Software, and expires 90 days from installation (or such other period as may be indicated within the Software). Upon expiration of the evaluation period, You must discontinue use of the Software, return to an original state any actions performed by the Software, and delete the Software entirely from Your system and You may not download the Software again unless approved in writing by an authorized representative of Licensor. The Software may contain an automatic disabling mechanism that prevents its use after a certain period of time. RESTRICTIONS

  • SAMPLE (If applicable and the project has specifications, insert the specifications into this section.)

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Interoperability To the extent required by applicable law, Cisco shall provide You with the interface information needed to achieve interoperability between the Software and another independently created program. Cisco will provide this interface information at Your written request after you pay Cisco’s licensing fees (if any). You will keep this information in strict confidence and strictly follow any applicable terms and conditions upon which Cisco makes such information available.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Random Testing Notwithstanding any provisions of the Collective Agreement or any special agreements appended thereto, section 4.6 of the Canadian Model will not be applied by agreement. If applied to a worker dispatched by the Union, it will be applied or deemed to be applied unilaterally by the Employer. The Union retains the right to grieve the legality of any imposition of random testing in accordance with the Grievance Procedure set out in this Collective Agreement.

  • System Logging The system must maintain an automated audit trail which can 20 identify the user or system process which initiates a request for PHI COUNTY discloses to 21 CONTRACTOR or CONTRACTOR creates, receives, maintains, or transmits on behalf of COUNTY, 22 or which alters such PHI. The audit trail must be date and time stamped, must log both successful and 23 failed accesses, must be read only, and must be restricted to authorized users. If such PHI is stored in a 24 database, database logging functionality must be enabled. Audit trail data must be archived for at least 3 25 years after occurrence.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!